Paris, France and Cambridge, MA, USA – June 4, 2018 

ENTEROME SA, a clinical-stage biotechnology company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications, will attend the Jefferies 2018 Global Healthcare Conference. The conference will be held in New York, June 5-8 and features an extensive range of public and private healthcare companies across the Biopharmaceuticals, Life Sciences, Healthcare Services, Healthcare IT and Medical Technology sectors. It hosted over 2,600 attendees in 2017.

---

Contact
Pierre Belichard, CEO
pbelichard@localhost

Media relations
Mark Swallow / Marine Perrier / David Dible
Citigate Dewe Rogerson
+44 207 638 9571
enterome@citigatedewerogerson.com

Investor relations
Lisa Pavelka
Rx Communications Group
Tel. +1 917 843 0223
lpavelka@rxir.com

---

Download the press release (.pdf format)

EN:    FR: